Table 1. SPR and GMR Sensors Based on Magnetic Nanoparticles.
sensor | SPMNP composition | NP size | analyte | detection limit | detection range | ref |
---|---|---|---|---|---|---|
SPR | streptavidin conjugated Fe2O3 magnetic nanoparticles | 50 nm | brain natriuretic peptide | ND | 0.025–1 ng/mL | (82) |
streptavidin conjugated superparamagnetic nanoparticles | 50 nm | Staphylococcal enterotoxin B | ND | 0.10–10 ng/mL | (83) | |
tosyl-activated superparamagnetic nanoparticles | 1 μm | prostate specific antigen | 10 fg/mL | 1 fg/mL–100 ng/mL | (52) | |
magnetic nanoparticles with iron oxide core | 220 ± 63 nm | beta human chorionic gonadotropin | 0.45 pM | ND | (84) | |
carboxyl group modified Fe3O4 magnetic nanoparticles | 10.5 nm | thrombin | 0.017 nM | 0.27–27 nM | (85) | |
core/shell Fe3O4/SiO2 nanoparticles | 16 nm | rabbit IgG | ND | 1.25–20 μg/mL | (86) | |
core/shell Fe3O4/Ag/SiO2 nanoparticles | 19 nm | rabbit IgG | ND | 0.30–20 μg/mL | (86) | |
core/shell Fe3O4/Au nanoparticles modified with 3-mercaptopropionic acid (MPA) | 8–30 nm | human IgM | ND | 0.30–20 μg/mL | (87) | |
Iron oxide carboxyl-modified magnetic nanoparticles | 200 nm | Ochratoxin A | 0.94 ng/mL | 1–50 ng/mL | (88) | |
core/shell Fe3O4/Au nanoparticles | 25–30 nm | A-fetoprotein | 0.65 ng/mL | 1.0–200.0 ng/mL | (54) | |
Fe3O4–Au nanorod (50 × 15 with 0.05 mmol/L AgNO3, 65 × 30 with 0.1 mmol/L AgNO3) | goat IgM | ND | 0.15–40.00 μg/mL | (55) | ||
Fe3O4/Ag/Au nanocomposite | 35 nm | Dog IgG | 0.15 μg/mL | 0.15–40.00 μg/mL | (56) | |
carboxyl group modified Fe3O4 magnetic nanoparticles | 6.53 ± 0.22 nm | Salmonella enteritidis | 14 cfu/mL | 14–1.4 × 109 cfu/mL | (89) | |
GMR | streptavidin conjugated superparamagnetic nanoparticles | 300 nm | parathyroid hormone | 10 pM | ND | (90) |
cubic FeCo nanoparticles | 12.8 ± 1.58 nm | Interleukin-6 | ND | 125 fM–41.5 pM | (91) | |
streptavidin conjugated Fe2O3 nanoparticles | 50 nm | Aflatoxin B1 | 50 pg/mL | 0.050–50 ng/mL | (62) | |
streptavidin conjugated microbeads | ND | allergen Ara h 1 | 7. 0 ng/mL | 7.0–>2000 ng/mL | (61) | |
streptavidin conjugated microbeads | ND | allergen Ara h 2 | 0.2 ng/mL | 0.2–>250 ng/mL | (61) | |
streptavidin conjugated microbeads | ND | allergen gliadin | 1.5 ng/mL | 1.5–4000 ng/mL | (61) | |
streptavidin conjugated cubic FeCo nanoparticles | 12.8 ± 1.58 nm | endoglin | 83 fM | ND | (70) | |
streptavidin conjugated superparamagnetic nanoparticles | 50 nm | Staphylococcal enterotoxin A | 0.1 ng/mL | ND | (64) | |
streptavidin conjugated superparamagnetic nanoparticles | 50 nm | toxic shock syndrome toxin | 0.3 ng/mL | ND | (64) | |
streptavidin conjugated magnetic nanoparticles | ND | Flt3 ligand | ND | 0.020–3 μg/mL | (59) | |
streptavidin conjugated magnetic nanoparticles | ND | serum amyloid A1 | ND | 3–50 ng/mL | (59) | |
streptavidin conjugated magnetic nanoparticles | ND | influenza A virus | 1.5 × 102 TCIDa 50/mL | 1.5 × 102–1.0 × 105 TCID 50/mL | (66) |
TCID, tissue culture infective dose.